NextCure (NXTC)

• Market cap: $23.2M
• 1 day: -4.63%
• 5 days: -11.94%
• 1 month: -29.25%
• 3 months: -41.29%
• 6 months: -48.26%
• Year to date: -28.02%
• 1 year: -28.02%
• 5 years: -98.68%
• 10 years: -95.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.

Employees: 82

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

9.48% less ownership

Funds ownership: 66.18% [Q2] → 56.7% (-9.48%) [Q3]

10% less funds holding

Funds holding: 49 [Q2] → 44 (-5) [Q3]

26% less capital invested

Capital invested by funds: $29.4M [Q2] → $21.7M (-$7.7M) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 383% upside
• Avg. target: $4 383% upside
• High target: $4 383% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 14% 1-year accuracy 21 / 150 met price target

383% upside $4

Buy Maintained

11 Nov 2024